重大事件即時報告 8-K 2026-05-14

Ocugen, Inc.（納斯達克：OCGN）於2026年5月14日提交8-K申報，披露兩項高層人事變動，即時生效。

AI 繁中摘要

Ocugen, Inc.（納斯達克：OCGN）於2026年5月14日提交8-K申報，披露兩項高層人事變動，即時生效。😷

首席醫療官（CMO）Huma Qamar醫生已於2026年5月8日離職。同日，公司委任Mohamed Genead醫生為代理／臨時首席醫療官，填補空缺。

此類管理層變動屬於常規企業運作，但CMO主導臨床開發策略，短期內可能影響研發項目溝通或監管對接節奏。投資者宜關注公司後續對臨床試驗時間表及監管提交計劃的更新。🤔

是次申報僅為人事公告，未涉財務業績或業務重大變動。

展開英文正文

false
 0001372299
 
 
 
 
 
 
 
 0001372299
 
 
 2026-05-08
 2026-05-08
 
 
 
 iso4217:USD
 
 
 xbrli:shares
 
 
 
 
 iso4217:USD
 
 
 xbrli:shares
 
 
 
 
 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

 of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):
May 8, 2026

 

OCUGEN, INC.

(Exact name of registrant as specified in its charter)

 

 
 Delaware
  
 001-36751
  
 04-3522315

 
 (State or other jurisdiction

 of incorporation)
  
 (Commission File

 Number)
  
 (IRS Employer

 Identification No.)

 
 

 
 
 11 Great Valley Parkway

 Malvern, Pennsylvania 

  
 19355

 
 (Address of principal executive offices)
  
 (Zip Code)

 
 

(484) 328-4701

Registrant’s telephone
number, including area code: 

 

N/A

(Former name or former address, if changed
since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):

 

 
 ¨
 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 
  
  

 
 ¨
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 
  
  

 
 ¨
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 
  
  

 
 ¨
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 

Securities registered pursuant to Section 12(b) of the Act:

 

 
 Title of each class
  
 Trading

Symbol(s)
  
 Name of each exchange 

on which registered

 
 Common Stock, par value $0.01 per share
  
 OCGN
  
 
 The Nasdaq Stock Market LLC

 (The Nasdaq Capital Market)

 
 

Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

  

  

 

 

Item 5.02. Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Effective May 8, 2026, Huma Qamar, M.D., MPH, CMI, separated from
Ocugen, Inc. (the “Company”) as its Chief Medical Officer.

 

Item 8.01. Other Events.

 

Effective May 8, 2026, the Company appointed Mohamed Genead, M.D.,
M.Sc., as Acting/Interim Chief Medical Officer.

 

 2

  

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 
  
  
 OCUGEN, INC.

 
  
  
  

 
 Date: May 14, 2026
 By:
 /s/ Shankar Musunuri

 
  
  
 Name: Shankar Musunuri

 
  
  
 Title: Chairman, Chief Executive Officer, & Co-Founder

 
 

 3